![]() 5 In contrast, data from studies in older adults receiving a single dose of BNT162b2 have yielded mixed results. 2, 3, 4 In a more recent UK study, two doses were shown to be approximately 85%–90% effective in adults aged 70 years and older. 1 Accumulating data from the general population in Israel and early studies in US healthcare workers confirmed that vaccination with a two-dose regimen confers 94.6% and 95% protection against symptomatic infection and severe disease, respectively, 1 to 2 weeks after the second dose. Among approved vaccines, the BNT162b2 vaccine (Comirnaty, Pfizer-BioNTech) relies on novel mRNA technology, where mRNA is packaged into lipid nanoparticles to deliver genetic instructions for human cells to produce the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Vaccine development has been a success story of the coronavirus disease 2019 (COVID-19) pandemic.
0 Comments
Leave a Reply. |